Worth your time

Drug pricing experts will remember the debate over Sarepta’s drug Exondys 51, which treats Duchenne’s muscular dystrophy. As STATreports, the company is years behind schedule to prove that there’s a benefit to taking it, even though it’s already on the market — and can cost $1 million annually. — Erin Mershon

More and more young people still see their childhood doctor, the Washington Post reports, partly a result of Obamacare allowing adults to stay on their parents’ health insurance until age 26 and partly because they simply see no point in moving on. — Lev Facher

The New York Times tells the story of a nun, a doctor, and a lawyer and their 20-plus-year struggle to quell the opioid epidemic in their hometown. — Nicholas Florko